CagriSema: The GLP-1 and Amylin Combination With an FDA Decision Expected Before Year-End

Key takeaways

• CagriSema is a once-weekly injectable fixed-dose combination of semaglutide 2.4 mg and cagrilintide 2.4 mg, a long-acting amylin analogue, currently under FDA review for weight management in adults with obesity or overweight.
• Novo Nordisk filed the New Drug Application (NDA) on 18 December 2025, based on the pivotal REDEFINE-1 and REDEFINE-2 trials. An FDA decision is expected in Q4 2026, though no confirmed PDUFA date has been publicly announced.
• In REDEFINE-1, CagriSema produced 22.7 % average weight loss over 68 weeks in patients who adhered to treatment — materially ahead of semaglutide alone at 16.0 % in the same trial.
• REDEFINE-4, a head-to-head comparison against tirzepatide 15 mg, reported 23 % weight loss at 84 weeks but missed its pre-specified non-inferiority endpoint.
• No EMA submission for weight management has been confirmed, and no MHRA pathway has been announced for the United Kingdom, meaning NICE appraisal and NHS access decisions would follow any future licence.

What CagriSema is

CagriSema is an investigational once-weekly subcutaneous combination medicine developed by Novo Nordisk. Novo Nordisk's NDA filing describes it as a fixed-dose combination of cagrilintide 2.4 mg, a long-acting amylin analogue, and semaglutide 2.4 mg, the GLP-1 receptor agonist already approved as Wegovy and Ozempic.

The two components target distinct but complementary pathways. Semaglutide acts on the GLP-1 receptor, reducing appetite and slowing gastric emptying. Amylin — a peptide co-secreted with insulin from pancreatic beta cells — acts centrally to suppress appetite, slow gastric emptying, and reduce post-meal glucagon, by a mechanism separate from GLP-1 signalling. Cagrilintide is a synthetic long-acting version of amylin designed for once-weekly dosing. If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment on the market.

The compound is under investigation across two Phase 3 clinical programmes: REDEFINE (adults with overweight or obesity) and REIMAGINE (adults with type 2 diabetes). Only the REDEFINE programme forms the basis of the current NDA.

REDEFINE pivotal trials: what the data show

REDEFINE-1 (adults without type 2 diabetes)

REDEFINE-1 enrolled 3,417 adults with overweight or obesity and ran for 68 weeks. Participants who adhered to treatment lost an average of 22.7 % of their body weight over 68 weeks, with 60 % of adherent participants achieving 20 % or greater weight loss and 23 % achieving 30 % or greater. Semaglutide alone produced 16.0 % weight loss in the same trial, while the placebo arm showed 1.8 %, indicating a clear additive contribution from cagrilintide.

REDEFINE-2 (adults with type 2 diabetes)

In REDEFINE-2, average weight loss was 15.7 % with full adherence. Novo Nordisk has stated it will separately approach regulators on a type 2 diabetes indication following these results, meaning the current NDA covers obesity management only.

REIMAGINE-2 (type 2 diabetes, supportive data)

Novo Nordisk presented REIMAGINE-2 data at the American Diabetes Association's 2026 Scientific Sessions. CagriSema demonstrated superior HbA1c reduction of 1.91 percentage points and weight loss of 14.2 % in REIMAGINE-2 versus semaglutide, across all tested doses. These results informed commercial interest but are not part of the REDEFINE obesity submission.

REDEFINE-4: the head-to-head complication

The February 2026 readout of REDEFINE-4 introduced an important caveat. REDEFINE-4 reported 23 % weight loss for CagriSema at 84 weeks, but the trial missed its pre-specified non-inferiority endpoint against tirzepatide 15 mg. This result does not affect the NDA itself, which was filed in December 2025 based on placebo-controlled data, but it does complicate the commercial positioning of the drug.

The REDEFINE-1 headline numbers of 20.4–22.7 % sit below Zepbound's SURMOUNT-1 result of 22.5 % but above Wegovy's STEP-1 result of 14.9 %. In a market where tirzepatide already holds established reimbursement and physician familiarity, differentiating on weight-loss magnitude alone appears insufficient, particularly given the failed non-inferiority test. Novo Nordisk's clinical programme also includes CagriSema's effects on cardiometabolic and diabetes endpoints, which may ultimately define the regulatory label more than weight-loss percentage.

FDA review status and timeline

Novo Nordisk filed the NDA on 18 December 2025, based on REDEFINE-1 and REDEFINE-2 data. As of July 2026, neither the FDA nor Novo Nordisk has publicly confirmed a PDUFA date. Company guidance points to a decision in Q4 2026, consistent with the standard ten-to-twelve month review clock for a new molecular entity.

The filing does not appear to carry Priority Review, which would have compressed the timeline to six months. No advisory committee meeting has been scheduled, although the FDA retains discretion to convene an external expert panel. If approved in Q4 2026, commercial launch would follow in early 2027, allowing for manufacturing scale-up and pharmacy distribution setup.

UK and European regulatory picture

The UK regulatory position is currently a gap in the public record. No EMA submission for weight management has been confirmed by Novo Nordisk, and no MHRA pathway has been announced for the United Kingdom, where NICE appraisal and NHS access decisions would follow any future licence. EU approval typically follows FDA approval by three to six months, though a post-Brexit UK licence is a separate process.

For UK research-procurement teams, the practical implication is straightforward: CagriSema remains an unapproved investigational product, and semaglutide itself — the well-characterised GLP-1 component at its core — is the more established research entity. Any laboratory work on the dual mechanism would require separate characterisation of the amylin analogue component alongside the GLP-1 pathway.

Broader context: where CagriSema fits in the GLP-1 pipeline

The GLP-1 agonist pipeline in 2026 is characterised by escalating efficacy across successive mechanisms. The class began with semaglutide near 15 %, advanced to the dual agonist tirzepatide near 21 %, and now reaches the triple agonist retatrutide above 28 %, while oral pills and monthly injectables crowd in behind them. CagriSema sits somewhere between tirzepatide and retatrutide in terms of headline weight-loss figures, but uses a different secondary mechanism — amylin rather than GIP or glucagon.

Novo Nordisk is also advancing zenagamtide (formerly amycretin), a unimolecular GLP-1 and amylin receptor agonist under investigation for both oral and subcutaneous administration. Zenagamtide represents the next iteration of the amylin-plus-GLP-1 concept in a single molecule. Should CagriSema gain approval, it would serve as the immediate near-term commercial entry for this mechanism class while zenagamtide advances through later-stage trials.

For the research sector, the CagriSema dossier also provides a model for studying dual-mechanism peptide combinations: how additive effects are characterised across separate receptor targets, what the implications are for tolerability profiling, and how regulators assess a combination NDA where one component is already approved.

What to watch

• PDUFA date confirmation: No public target action date has been announced. An FDA communication confirming the date — or any request for additional data — would be the next material disclosure.
• Advisory committee scheduling: The FDA retains discretion to convene a panel. Given the class-wide political attention on obesity drugs and GLP-1 compounding, external review is plausible.
• MHRA/EMA submissions: Any announcement of a European or UK regulatory filing would mark a significant step toward access outside the United States.
• Manufacturing capacity: PolyPeptide Group — whose acquisition by Samsung Biologics is progressing toward a formal tender offer in late August 2026 — produces peptide active pharmaceutical ingredients relevant to this class, and capacity constraints remain a structural concern for any new obesity product launch.